Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Qian Website

Xiaolan Qian, Ph.D.

Laboratory of Cellular Oncology
Signaling and Oncogenesis Section
Staff Scientist
Center for Cancer Research
National Cancer Institute
Building 37, Room 4112
37 Convent Drive
Bethesda, MD 20892-4263


Dr. Qian completed her M.B. in pediatrics and M.S. in biochemistry at Shanghai Second Medical University, Shanghai, China. She also obtained a certificate issued by the ECFMG (Educational Commission for Foreign Medical Graduates) in the U.S.A. for training in human genetics at the University of Pennsylvania School of Medicine (Philadelphia, PA). Dr. Qian then earned a Ph.D. in biology at the University of Pennsylvania. Her thesis work was completed in Dr. Mark Greene's laboratory. It elucidates the mechanism of inter-receptor activation by the tyrosine kinases EGFR and erbB2, and their cooperation in cellular signaling and biology. After a postdoctoral fellowship in Dr. Greeneā€™s laboratory, she joined the Laboratory of Cellular Oncology (LCO) at CCR. Her major projects in LCO have included the use of cell biological approaches to understand normal and neoplastic cell growth and signaling resulting from the perturbation of cell-cell adhesions, and the regulation of small GTPases (such as Ras, Rap, Rho and Cdc42) by oncogenic GEFs or tumor suppressive GAPs.


My major projects have focused on cell growth and signaling affected by certain oncogenes and tumor suppressors.

In one of my early studies in this area, I explored that tumor suppressor E-cadherin (an essential adhesion protein) can negatively regulate, in an adhesion-dependent manner, the ligand-dependent activation of divergent classes of receptor tyrosine kinases (RTKs), by inhibiting their ligand-dependent activation in association with decreases in receptor mobility and in ligand-binding affinity. Abrogation of E-cadherin regulation may contribute to the frequent ligand-dependent activation of RTK in tumors.

In a collaborative project with Dr. Eugene Santos, I found that the two Ras-specific exchanging factors, Sos1 and Sos2, differ in placenta expression and signaling properties in conjunction with EGFR or v-Src.

In collaboration with Dr. Nicolae Popescu, I worked on deleted in liver cancer-1 (DLC-1), a tumor suppressor with Rho-specific GAP activity. I developed a series of assays that determined the full activity of DLC1 requires its specific interaction with several focal adhesion proteins (such as tensin, talin, FAK, vinculin, etc). I also demonstrated that the Src-dependent phosphorylation on tensin-3 protein, including in its SH2 domain, is critical to its tumorigenic and metastatic activities.

My most recent project is focused on the regulation of the Dbl oncogene, a guanine exchanging factor for Rho/Cdc42. The post-translational modification on Dbl by certain kinase on the DH and/or PH domains make important contributions to modulating its GEF activity and bioactivity.

In addition to these projects within LCO, I have established collaborative projects with several extramural laboratories. Currently, I am collaborating with Dr. Dunrui Wang (W2 Motif) to compare the gene expression and tumor suppressor activity of DLC1-3 related to lung cancer prognosis using bioinformatics analysis. Two other collaborative efforts are to further understand the molecular details of the interaction between DLC1 and talin with an excellent structural biologist, Dr. Igor Barsukov, at the University of Liverpool, United Kingdom, and to explore the mechanism of DLC1 negative regulation on talin with an integrin expert, Dr. Sandford Shattil, at the University of California San Diego.

This page was last updated on 7/10/2014.